This article explores the role of fibrates in cholesterol management, how they work, their types, potential side effects, and ...
The mineralocorticoid receptor antagonist did not reduce primary outcomes in the CLEAR SYNERGY trial, but there was a suggestion that it did prevent new or worsening heart failure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback